On the evening of December 18, Huadong Medicine issued a "statement letter" in ***, saying: Recently,Hangzhou Chengze Pharmaceutical*** violated the agreement by carrying out marketing and product promotion activities of the agreed products in Suzhou, Hangzhou and other places in the name of "Huadong Medicine" without permission。The company does not assume any responsibility for the behavior of Chengze Pharmaceutical, and reserves the right to claim for relevant losses caused by relevant contractual remedies.
The activities mentioned in the statement letter refer to the global press conference of "Reducing Fees" held at the Hangzhou International Expo Center on December 16, which is contrary to the letterThe advertised product is the "star product" of Huadong Medicine, liraglutide, trade name Lilupin.
In July this year, Huadong Medicine's liraglutide biosimilar was approved for ** indication in China, becoming China's first domestic GLP-1** injection.
According to the press conference circulating on the Internet, the product named "Fei Zhen" was announced for the world premiere, and the relevant personnel advertised it as "the world's first GLP-1 weight reduction" when introducing the product. (sic).
Moreover,Li Bangliang, former chairman and current honorary chairman of Huadong Medicine, also appeared at the press conferenceand delivered a speech as "Chairman of Hangzhou Huadong Pharmaceutical Group Holdings" and "Chairman of Chengze Pharmaceutical".
Source: Events posted by Douyin users**.
The product was "promoted" in violation of regulations
It all started with this liraglutide press conference.
Huadong Medicine saidIn December this year, a wholly-owned subsidiary, Zhongmei Huadong, signed an agreement with Chengze Pharmaceutical, entrusting it to carry out marketing services for liraglutide injection pre-filled packaging and refills in specific medical institutions. However, "the entire activity of 'Reducing Philip' was not authorized by the company and the company was not aware of it".
Huadong Medicine even said that it had received inquiries from some investors, so it needed to be clarified.
Judging from the scene alone, this conference is indeed not like that organized by East China Medicine.
The main product promoted at the press conference was "the world's first GLP-1 weight reduction product", but other products were also promoted, especially the "Fei Zhen" product. Huadong Medicine said in an interview with ** reporters"Reducing Phenomen" is a product launched by Chengze Pharmaceutical, including meal replacement, "rilupine", weight management services, etc.
Source: Events posted by Douyin users**.
At the press conference,Li Bangliang introduced the product "Reducing Fei Zhen" in detailIt is said that "the scientific and organic combination of liraglutide and 'Yue Xiaoyou' has formed a weight management product that combines Chinese and Western products that are the first in the world today - that is, an organic combination of medicine and food science." The "Yue Xiaoyou" he mentioned is a management model of 5+25 days of intermittent eating.
According to the online biography**, Li Bangliang's speech was mainly aimed at "the leaders of medical aesthetic institutions across the country, and friends of medical aesthetic institutions in the United States, France and other countries and regions". On the online platform, most of the users of **activities** are beauticians and other related industry practitioners, and many of them are also promoting products to platform users as micro-businesses.
Interestingly, it was not only Li Bangliang who attended the press conferenceEven Fu Hang, chairman and general manager of Hangzhou Jiuyuan Gene, the developer of "Lilupin", also came。Jiuyuan Gene is a joint stock company of Huadong Pharmaceutical, which developed liraglutide injection, and Sino-US Huadong bought the exclusive rights of the new drug technology of liraglutide developed by Jiuyuan.
Source: Events posted by Douyin users**.
With the identities of these two people, both appeared at the event, it is no wonder that industry insiders are also confused.
As we all know, liraglutide is a prescription drug, and its prescription and use should be carried out under the guidance of a licensed physician。The promotion of "Reduction of Phenomen" is the promotion of the prescription drug liraglutide, and the public promotion of prescription drugs is suspected of violating the Drug Administration Law.
After all, Huadong Pharmaceutical is a listed company, and it is impossible to bear such illegal results, so it can only urgently issue a statement letter to dissociate itself from Chengze Pharmaceutical.
However, this Chengze Pharmaceutical, as well as the developer of "Yue Xiaoyou", Hangzhou Huadong Medicine Wuhe Derong Health Management, is not simple, and has a deep connection with Huadong Medicine. Huadong Medicine claims to make a claim, which is not "cutting the robe and breaking the righteousness", it is simply "killing relatives with righteousness".
Veteran Li Bangliang
As mentioned earlier,The chairman of Chengze Pharmaceutical is Li Bangliang, who is also the founder of Huadong Pharmaceutical, a listed company.
The predecessor of Huadong Pharmaceutical was Zhejiang Pharmaceutical Factory, which was established in 1952, and was renamed Hangzhou Huadong Pharmaceutical Factory in 1988. In 1992, the state-owned enterprise was restructured, and Li Bangliang was appointed as the director of the factory, and then there was Hangzhou Huadong Pharmaceutical Group, which was wholly state-owned, and Huadong Medicine, which was listed in 1999.
For a long time after 2000, Li Bangliang had another identity:Chairman and legal representative of Hangzhou Huadong Pharmaceutical Group Holdings.
This "Huadong Pharmaceutical Group Holdings" has no connection with the listed company Huadong Pharmaceutical and its shareholder Huadong Pharmaceutical Group, but in the early days of the company's establishment, the executives of "Huadong Pharmaceutical Group Holdings" were almost all the management of the listed company Huadong Medicine, including Li Bangliang himself.
Judging from the name, "Huadong Pharmaceutical Group Holdings" is more like a shell company established by the management of Huadong Pharmaceutical at that time, and the purpose may be for MBO, which was a very popular management buyout back then.
However, Huadong Medicine's MBO has not been able to make the trip"Huadong Pharmaceutical Group Holdings" only holds a part of the shares in the member companies of Huadong Pharmaceutical Group, including Jiuyuan Gene, Kangrun Pharmaceutical, East China Pharmaceutical Group New Drug Research Institute, etc. Among them, "Huadong Pharmaceutical Group Holdings" holds 95% of the equity of the New Drug Research Institute and holds 16% of Jiuyuan Gene2491% equity.
The predecessor of the Institute of New Drug Research was Hangzhou Institute of Bioengineering, which was founded in 1980. A number of Huadong Medicine's blockbuster varieties have been acquired by the New Drug Research Institute at low prices, including its largest fist product, acarbose.
Although Li Bangliang and other executives failed to achieve MBO, they spun off part of the business from the group to a certain extentIt is an indisputable fact that it has been accompanied by the development of East China Medicine.
According to the company's industrial and commercial change information, Li Bangliang no longer served as the legal representative of "Huadong Pharmaceutical Group Holdings" in 2015, when he was already in his seventies. In October this year, "Huadong Pharmaceutical Group Holdings" was renamed Hangzhou Huasheng Pharmaceutical Group***
Look at it this way,It is not surprising that Huadong Pharmaceutical, a listed company, handed over its core product liraglutide to Chengze Pharmaceutical, which is chaired by Li Bangliang, for promotion。However, Chengze Pharmaceutical held a controversial press conference, and Huadong Medicine could only cut it with a black face, otherwise it might face punishment from the drug regulatory department.
Management buyout is a unique phenomenon of China's state-owned enterprise restructuring in the late 90s, and the slightest carelessness will involve the legal risk of "private division of state-owned assets". Zheng Junhuai of Yili Group, Chu Shijian of Hongta Group and other business tycoons are all planted here. The most well-known case in the pharmaceutical industry is Zhao Xinxian of the former Sanjiu Group
As for whether the cooperation with Chengze Pharmaceutical will continue, Huadong Medicine told ** that it has not received a notice of termination of cooperation at present.
Written by Li Ao.
Edited by Jiang Yun Jia Ting.
Operated by Han Jinrui.
Disclaimer: Original content of the Health Knowledge Bureau, please do not do it without permission**